Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Clene Inc. CLNN

Clene Inc. is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson's disease and multiple sclerosis. It specializes in the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its CNM-Au8... see more

Recent & Breaking News (NDAQ:CLNN)

Evidence for Clene's CNM-Au8® as a Treatment for Repair and Remyelination in Multiple Sclerosis Presented in the Emerging Science Session at the 2024 American Academy of Neurology Annual Meeting

GlobeNewswire April 16, 2024

Clene Announces Peer-Reviewed Publication Characterizing the Protein Corona of the Investigational Neurodegenerative Disease Drug, CNM-Au8®

GlobeNewswire March 15, 2024

Clene Reports Full Year 2023 Financial Results and Recent Operating Highlights

GlobeNewswire March 13, 2024

Clene to Present at the 36th Annual ROTH Conference

GlobeNewswire March 7, 2024

Clene Presents Clinical Results of CNM-Au8® 30mg Treatment From Visionary-MS Trial Long-Term Extension at Annual ACTRIMS Forum 2024

GlobeNewswire February 29, 2024

Clene Reports Significant Survival Benefit With CNM-Au8® Treatment in ALS EAP Compassionate Use Programs

GlobeNewswire February 22, 2024

Clene Reports Significant Improvement in Vision and Cognition With CNM-Au8® Treatment in VISIONARY-MS Trial Long-Term Open Label Extension

GlobeNewswire January 8, 2024

Clene Provides Update on ALS Clinical Development Meeting With FDA

GlobeNewswire December 21, 2023

Clene Reports Reduction in Biomarker Plasma Neurofilament Light (NfL) Levels and Improved Survival With CNM-Au8® Treatment From HEALEY ALS Platform Trial Long-Term Open Label Extension

GlobeNewswire December 21, 2023

Clene Announces Peer-Reviewed Publication Describing CNM-Au8 Brain Target Engagement In Neurodegenerative Diseases

GlobeNewswire December 14, 2023

Clene Reports Third Quarter 2023 Financial Results and Operating Highlights

GlobeNewswire November 7, 2023

National Institutes of Health Awards $45.1 Million NINDS Grant for CNM-Au8® Study in ALS

GlobeNewswire October 5, 2023

Clene Announces Peer-Reviewed Publication Describing CNM-Au8 Catalytic Neuroprotective Mechanism of Action

GlobeNewswire September 28, 2023

Clene to Present at Cantor Fitzgerald Annual Global Healthcare Conference

GlobeNewswire September 25, 2023

Clene Reports Significant Long-Term Survival Improvement From CNM-Au8 Treatment in HEALEY ALS Platform Trial Compared to PRO-ACT Historical Controls

GlobeNewswire September 25, 2023

Clene to Present at Upcoming September Conferences

GlobeNewswire August 30, 2023

Clene Reports Significantly Improved Survival Benefit of 19.3 Months and Significantly Delayed Clinical Worsening in Rescue-Als Open-Label Extension Two Year Follow-Up

GlobeNewswire August 29, 2023

Clene Reports Second Quarter 2023 Financial Results and Operating Highlights

GlobeNewswire August 14, 2023

Clene to Present at the Canaccord Genuity 43rd Annual Growth Conference

GlobeNewswire August 2, 2023

Clene Announces Publication of Phase 2 CNM-Au8® Clinical Data for the Treatment of ALS in LANCET's eClinicalMedicine

GlobeNewswire June 26, 2023